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Background:  There is an emerging concern about the increased cancer risk associated with the use of angiotensin-receptor blockers (ARBs). The 
objective of this case-control study was to evaluate the risk of malignancy in diabetic patients who received ARBs.
Methods:  A total of 21,750 new diabetic patients who started anti-hypertensive treatment were identified from the Taiwan National Health 
Insurance claim database during the period of 1 July 2000 to 31 December 2000. As of 31 December 2007, incident cancer patients were included 
as cases and up to four age- and sex-matched controls were selected by risk-set sampling. Logistic regression models were applied to estimate the 
odds ratio (OR) and 95% confidence interval (CI) between ARB use and cancer incidence, adjusted for other types of anti-hypertensive drugs, insulin, 
oral hypoglycemic agents, statins, and underlying diseases.
Results:  Among the 1,281 incident cancer patients and 5104 controls, 333 (26.0%) and 1341 (26.3%) received ARBs (OR: 0.98, 95% CI: 
0.85~1.14), respectively. There was no statistically significant association between ARBs as a class effect and cancer incidence after adjustment for 
covariates (OR: 0.94, 95% CI: 0.80~1.10). Among the individual ARBs, losartan decreased the risk (OR: 0.78, 95% CI: 0.63~0.97) while candesartan 
and telmisartan possibly increased the risk (OR: 1.77, 95% CI: 1.04~3.02; OR: 1.53, 95% CI: 0.97~2.41) of occurrence of malignancy.
Conclusions:  The results did not show a class effect of ARBs on increasing cancer incidence in diabetic patients. However, the association with 
the occurrence of overall cancer varied across individual drugs and required further investigation.
